Research & Clinical Trials

The following research studies and clinical trials are being conducted by the Headache Center.


Can DFN-15 terminate migraine with allodynia?

Principle Investigator: Dr. Brian Grosberg

We are currently recruiting for this study.

Frequently asked Questions:

Q: What is the purpose of this study?
A: Medications that are often used to treat migraines are most effective in a short window of time after
the migraine begins. The purpose of this study is to determine whether or not an investigational drug
can treat a migraine after that window of time has passed. Many people who suffer from migraines
experience pain on their skin (allodynia) from things that would not normally cause pain, such as light
touch, when they have a migraine. We are trying to understand if the medication we give you will work
to stop the migraine headache in people who have the skin sensitivity and if it reduces the skin
sensitivity.

Q: Am I eligible to participate?
A: To be eligible to participate in this study, you must suffer from migraines and experience less than 16
headache days per month. You also must be medically cleared by your doctor to take this medication.

Q: What is the drug being studied?
A: This investigational drug is called DFN-15, or more commonly known as celecoxib, which is a nonsteroidal
anti-inflammatory drug (NSAID). This drug is commonly used to treat pain, inflammation, and
different types of arthritis, but is not currently approved for treating migraines.

Q: If am eligible and choose to participate, what will be my role in the study?
A: This study consists of two visits. The first visit will last about 30 minutes where you will have an
interview about your headaches and medical history to make sure you are eligible for the study. You will
have an opportunity to ask any questions that you have about the study. You will sign paperwork
confirming your participation in the study and be instructed to return to the Headache Center the next
time you have a migraine. The second visit will be on a separate day when you return to the Headache
Center with a migraine. During this visit you will receive the study medication if you have skin sensitivity
and spend about 2 hours at the clinic after receiving the treatment. It is possible that you are randomly
selected to receive a placebo treatment instead of the active treatment.

Q: What is a placebo drug?
A: A placebo is a treatment that will have no active therapeutic effect in treating your condition. The
placebo is designed to look and taste like the active treatment in order to prevent the participants from
knowing whether a treatment is active or inactive. Placebos are often used in research because
expectations about the effectiveness of the treatment can influence the results if the participants know
which treatment they receive (the placebo effect).


Status Migrainosus: Differentiating Between Responders and Non-responders in the Setup of Real-life Clinical Practice

Investigators: Dr. Rami Burstein, Beth Israel Deaconess Medical Center and Dr. Brian Grosberg, Hartford HealthCare Headache Center

We are currently recruiting for this study.

Dr. Brian Grosberg, Medical Director of the Hartford HealthCare Headache Center, is co-winner of the Migraine Research Foundation's first Impact Award that will fund a 3-year study on Status Migrainosus.

To determine if you are eligible to participate in the status migrainosus study, you must first become a new patient of the Hartford HealthCare Headache Center. Click here to learn how to become a new patient.

Frequently Asked Questions

Q: What is “status migrainosus"?
A:
Status migrainosus is a severe form of migraine that lasts for 3 or more days.

Q: What is the status migrainosus study?
A:
The goal of the study is to explore how status migrainosus sufferers respond to different treatments and determine what treatments work best for different types of patients.

Q: If I am eligible and decide to participate, what will be my role in the study?
A:
There will be 4 parts to the study.

  • In part 1, you will have an interview about your headaches and complete a secure, online Headache Questionnaire if you have not done so already.
  • In part 2, you will receive a treatment that the headache specialist thinks will best treat your headaches. You will know what treatment you are receiving and will be involved in making this decision. At this visit, you will also be taught how to keep a detailed headache diary.
  • In part 3, you will complete headache diaries for 30 days. The diary for the first day will be by the hour and the rest of the diaries will be daily for the next 29 days.
  • In part 4, you will have another meeting with the headache specialist. During this meeting, you will be asked to explain your headache diaries in detail so that the headache specialist can figure out whether you have responded to treatment or not.

Q: How can my participation in this study help me and other migraine sufferers?
A:
By participating in this study, you can help take the “guess work” out of treating migraine that lasts continuously for 3 or more days. This may help to shorten and improve treatment for you and migraine sufferers worldwide.


Migraine Treatment with Nerivio Migra Neurostimulation Device

Recruitment has completed for this study.

Headache Center